Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study

被引：0
|
作者：
Zirwas, Matthew [1 ,2 ]
Draelos, Zoe D. [3 ]
DuBois, Janet [4 ]
Kircik, Leon [5 ]
Moore, Angela [6 ]
Gold, Linda Stein [7 ]
Higham, Robert C. [8 ]
Navale, Lynn [8 ]
Burnett, Patrick [8 ]
Berk, David R. [8 ]
机构：
[1] Prob Med Res, Dermatologists Cent States, Waterloo, ON, Canada
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Dermatol Consulting Serv, High Point, NC USA
[4] DermResearch Inc, High Point, NC USA
[5] Icahn Sch Med Mt Sinai, Indiana Med Ctr, Phys Skin Care PLLC & Skin Sci PLLC, New York, NY 10029 USA
[6] Arlington Ctr Dermatol, Arlington, TX USA
[7] Henry Ford Med Ctr, Detroit, MI USA
[8] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
28588
引用
收藏
页码：AB47 / AB47
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety results of a randomized, double-blind, vehicle-controlled phase 2 study of roflumilast foam 0.3% in patients with seborrheic dermatitis
    Zirwas, M.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 13 - 13
  • [2] Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial
    Zirwas, Matthew J.
    Draelos, Zoe D.
    DuBois, Janet
    Kircik, Leon H.
    Moore, Angela Y.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bukhalo, Michael
    Bruce, Suzanne
    Eads, Kimmie
    Green, Lawrence J.
    Guenthner, Scott T.
    Ferris, Laura K.
    Forman, Seth B.
    Kempers, Steven E.
    Lain, Edward
    Lynde, Charles W.
    Pariser, David M.
    Toth, Darryl P.
    Yamauchi, Paul S.
    Higham, Robert C.
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    [J]. JAMA DERMATOLOGY, 2023, 159 (06) : 613 - 620
  • [3] Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Bhatia, Neal
    DuBois, Janet
    Forman, Seth B.
    Gooderham, Melinda
    Green, Lawrence
    Guenthner, Scott T.
    Hebert, Adelaide A.
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Kato, Saori
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (05) : 986 - 993
  • [4] Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
    Kircik, Leon H.
    Alonso-Llamazares, Javier
    Bhatia, Neal
    Bukhalo, Michael
    Devani, Alim R.
    Draelos, Zoe D.
    DuBois, Janet
    Gooderham, Melinda J.
    Kempers, Steven E.
    Lain, Edward
    Lee, Mark
    Moore, Angela
    Murrell, Dedee F.
    Papp, Kim A.
    Pariser, David M.
    Sinclair, Rodney
    Zirwas, Matthew
    Burnett, Patrick
    Higham, Robert C.
    Krupa, David
    Berk, David R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (04) : 392 - 399
  • [5] A randomized, double-blind, vehicle-controlled phase 2b study of once-daily roflumilast foam 0.3% for scalp and body psoriasis
    Kircik, L. H.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 13 - 13
  • [6] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus
    Blauvelt, Andrew
    Draelos, Zoe D.
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela Y.
    Papp, Kim A.
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David R.
    Chu, David H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [7] Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of Pruritus
    Blauvelt, Andrew
    Draelos, Zoe
    Gooderham, Melinda
    Lain, Edward
    Moore, Angela
    Papp, Kim
    Zirwas, Matthew
    Krupa, David
    Burnett, Patrick
    Berk, David
    Chu, David
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156
  • [8] EFFICACY AND SAFETY OF ROFLUMILAST FOAM 0.3% IN PATIENTS WITH SEBORRHEIC DERMATITIS IN A PHASE 3 TRIAL: ASSESSMENT OF PRURITUS
    Blauvelt, A.
    Draelos, Z. D.
    Gooderham, M.
    Lain, E.
    Moore, A. Y.
    Papp, K. A.
    Zirwas, M.
    Krupa, D.
    Burnett, P.
    Berk, D. R.
    Chu, D. H.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S59 - S59
  • [9] A phase 3 double-blind, randomized, vehicle-controlled study of desonide foam in pediatric and adolescent patients with mild to moderate atopic dermatitis
    Friedlander, SF
    Loss, R
    Schlessinger, J
    Potts, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB85 - AB85
  • [10] Randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis
    Warshaw, E
    Wohlhuter, J
    Drake, D
    Zeller, S
    Wenner, R
    Bowers, S
    Schultz, J
    Parneix-Spake, A
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (01) : A3 - A3
12345